OBJECTIVE: Cancer therapies lead to chest pain (CP), shortness of breath (SOB), and/or tachydysrhythmias (TACH Y) requiring cardiac risk stratification including coronary computed tomographic angiography (CCTA). We posit that cancer patients with CP, SOB and/or TACH Y have greater odds of having coronary artery disease (CAD) identified by CCTA than those that do not. METHODS: Eligibility for this IRB-approved retrospective observational cohort included those with cancer that had CCTA performed. Groups were stratified with and without CP, SOB, and/or TACH Y. Electronic medical records were mined for appropriate CPT codes from 01012010 to 08312013. Demographics, cancer type, and clinical outcomes were obtained. Standard t tests, odds ratios, and frequencies were used. RESULTS: Of 176 participants identified; 84 were male (48 %) and 118 were Caucasian (67 %). Of those, 100/176 (57 %) had CP, SOB, and/or TACH Y; 72/100 (72 %) had CP; 10/100 (10 %) had TACH Y; and 18/100 (18 %) had SOB. Of the 72 with CP, 40 (56 %) had CAD; of the 10 with TACH Y, 6 (60 %) had CAD; of the 18 with SOB, and 10 (56 %) had CAD. Thus, a 2.6-fold increased odds of having CAD (56/100 = 56 %) compared to 25/76 (33 %) in the group with cancer without CP, SOB, and/or TACH Y (95 % CI = 1.40 to 4.83; p = 0.003). CONCLUSION: Cancer patients with CP, SOB, and/or TACH Y have a 2.6-fold increased odds of having CAD compared to cancer patients without CP, SOB, and/or TACH Y (95 % CI = 1.40 to 4.83; p = 0.003).
OBJECTIVE:Cancer therapies lead to chest pain (CP), shortness of breath (SOB), and/or tachydysrhythmias (TACH Y) requiring cardiac risk stratification including coronary computed tomographic angiography (CCTA). We posit that cancerpatients with CP, SOB and/or TACH Y have greater odds of having coronary artery disease (CAD) identified by CCTA than those that do not. METHODS: Eligibility for this IRB-approved retrospective observational cohort included those with cancer that had CCTA performed. Groups were stratified with and without CP, SOB, and/or TACH Y. Electronic medical records were mined for appropriate CPT codes from 01012010 to 08312013. Demographics, cancer type, and clinical outcomes were obtained. Standard t tests, odds ratios, and frequencies were used. RESULTS: Of 176 participants identified; 84 were male (48 %) and 118 were Caucasian (67 %). Of those, 100/176 (57 %) had CP, SOB, and/or TACH Y; 72/100 (72 %) had CP; 10/100 (10 %) had TACH Y; and 18/100 (18 %) had SOB. Of the 72 with CP, 40 (56 %) had CAD; of the 10 with TACH Y, 6 (60 %) had CAD; of the 18 with SOB, and 10 (56 %) had CAD. Thus, a 2.6-fold increased odds of having CAD (56/100 = 56 %) compared to 25/76 (33 %) in the group with cancer without CP, SOB, and/or TACH Y (95 % CI = 1.40 to 4.83; p = 0.003). CONCLUSION:Cancerpatients with CP, SOB, and/or TACH Y have a 2.6-fold increased odds of having CAD compared to cancerpatients without CP, SOB, and/or TACH Y (95 % CI = 1.40 to 4.83; p = 0.003).
Authors: E M Antman; M Cohen; P J Bernink; C H McCabe; T Horacek; G Papuchis; B Mautner; R Corbalan; D Radley; E Braunwald Journal: JAMA Date: 2000-08-16 Impact factor: 56.272
Authors: Charles V Pollack; Frank D Sites; Frances S Shofer; Keara L Sease; Judd E Hollander Journal: Acad Emerg Med Date: 2005-12-19 Impact factor: 3.451
Authors: Adam H Miller; Paul E Pepe; Ron Peshock; Rafia Bhore; Clyde C Yancy; Lei Xuan; Margarita M Miller; Gisselle R Huet; Clayton Trimmer; Rene Davis; Rebecca Chason; Micheal T Kashner Journal: Acad Emerg Med Date: 2011-05 Impact factor: 3.451
Authors: L Goldman; E F Cook; D A Brand; T H Lee; G W Rouan; M C Weisberg; D Acampora; C Stasiulewicz; J Walshon; G Terranova Journal: N Engl J Med Date: 1988-03-31 Impact factor: 91.245
Authors: James A Goldstein; Michael J Gallagher; William W O'Neill; Michael A Ross; Brian J O'Neil; Gilbert L Raff Journal: J Am Coll Cardiol Date: 2007-02-12 Impact factor: 24.094
Authors: Ronald P Karlsberg; Matthew J Budoff; Louise E J Thomson; John D Friedman; Daniel S Berman Journal: Rev Cardiovasc Med Date: 2009 Impact factor: 2.930